Literature DB >> 955744

Some international differences in treatment and survival in breast cancer.

A S Morrison, C R Lowe, B MacMahon, B Ravnihar, S Yuasa.   

Abstract

In a recent study, 5-year survival rates for breast cancer patients in Boston (Massachusetts), Glamorgan (Wales), Slovenia (Yugoslavia) and Tokyo (Japan) were 57.3%, 49.5%, 41.9% and 74.9%, respectively. In this report, data are presented on the types of treatment used in the four areas and on the relationship of differences in treatment practices to the differences in survival rates. Generally, surgically treated patients who also had radiotherapy had lower survival rates than patients in the same area who had similar operations without radiotherapy. In each area, the survival rate was higher for patients who had radical mastectomy than for those who had simple mastectomy. The Japanese patients had the highest survival rate within nearly every treatment and extent-treatment category. Thus, the high survival rate of these patients was not explained by the variables considered. Survival differences between Boston, Glamorgan and Slovenia were largely explained by differences in extent of disease and type of treatment. As the nature of the treatment--survival trends was consistent with the interpretation that treatment tended to be selected according to apparent prognosis, the degree to which treatment customs were determinants of the differences in survival rate among the three areas is uncertain.

Entities:  

Mesh:

Year:  1976        PMID: 955744     DOI: 10.1002/ijc.2910180302

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  13 in total

1.  Dietary intervention as adjuvant therapy in breast cancer patients--a feasibility study.

Authors:  L E Holm; E Nordevang; E Ikkala; L Hallström; E Callmer
Journal:  Breast Cancer Res Treat       Date:  1990-09       Impact factor: 4.872

Review 2.  Ethnic variation in breast cancer survival: a review.

Authors:  L Le Marchand
Journal:  Breast Cancer Res Treat       Date:  1991-05       Impact factor: 4.872

Review 3.  Geographical variation in endocrine function and its relation to breast cancer incidence: some general considerations.

Authors:  R D Bulbrook
Journal:  Breast Cancer Res Treat       Date:  1991-05       Impact factor: 4.872

4.  A breast cancer Nutrition Adjuvant Study (NAS): protocol design and initial patient adherence.

Authors:  R T Chlebowski; D W Nixon; G L Blackburn; P Jochimsen; E F Scanlon; W Insull; I M Buzzard; R Elashoff; R Butrum; E L Wynder
Journal:  Breast Cancer Res Treat       Date:  1987-10       Impact factor: 4.872

Review 5.  Adjuvant dietary fat intake reduction in postmenopausal breast cancer patient management. The Women's Intervention Nutrition Study (WINS).

Authors:  R T Chlebowski; D Rose; I M Buzzard; G L Blackburn; W Insull; M Grosvenor; R Elashoff; E L Wynder
Journal:  Breast Cancer Res Treat       Date:  1992-01       Impact factor: 4.872

Review 6.  Progress in understanding breast cancer: epidemiological and biological interactions.

Authors:  P Boyle; R Leake
Journal:  Breast Cancer Res Treat       Date:  1988-05       Impact factor: 4.872

7.  Histopathologic and dietary prognostic factors for canine mammary carcinoma.

Authors:  F S Shofer; E G Sonnenschein; M H Goldschmidt; L L Laster; L T Glickman
Journal:  Breast Cancer Res Treat       Date:  1989-01       Impact factor: 4.872

8.  Height, weight, and risk of breast cancer relapse.

Authors:  T Eberlein; R Simon; S Fisher; M E Lippman
Journal:  Breast Cancer Res Treat       Date:  1985       Impact factor: 4.872

9.  Five-year survival of women with breast cancer in northern Alberta.

Authors:  P E Burns; K Freund; A W Lees; M Hurlburt; M Grace
Journal:  Can Med Assoc J       Date:  1979-09-08       Impact factor: 8.262

10.  Body size and survival in premenopausal breast cancer.

Authors:  E R Greenberg; M P Vessey; K McPherson; R Doll; D Yeates
Journal:  Br J Cancer       Date:  1985-05       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.